Table of Contents
Mentioned in this article
Illumina, Inc. (ILMN) stock is lower by 2.24% over the past week and gets a Bearish rating from InvestorsObserver Sentiment Indicator.
What is Stock Sentiment?
Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score.
As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend.
Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive.
InvestorsObserver‘s Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend.
Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .
What’s Happening With ILMN Stock Today?
Illumina, Inc. (ILMN) stock has fallen -1.88% while the S&P 500 is up 0.85% as of 3:41 PM on Tuesday, Jul 18. ILMN is down -$3.46 from the previous closing price of $184.14 on volume of 1,144,571 shares. Over the past year the S&P 500 has gained 19.06% while ILMN is down -3.53%. ILMN lost -$28.58 per share in the over the last 12 months.
More About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina’s high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Click Here to get the full Stock Report for Illumina, Inc. stock.